---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-110370"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-08-20T23:59:59+00:00"
generated_at: "2026-05-17T11:09:39.079996+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Iterum launches ORLYNVAH, first oral penem antibiotic in U.S., for uUTI

## Summary
- FDA approved ORLYNVAH in Oct 2024; commercial launch announced Aug 20, 2025.
- First oral penem antibiotic in U.S.; first new branded uUTI product in >25 years.
- 57% of initial uUTIs resistant to at least one antibiotic class per 2024 study.
- Copay savings program allows eligible patients to get ORLYNVAH for as low as $25.
- CEO cites urgent need for new oral therapies amid rising antibiotic resistance.

## SEC filing metadata
- accession: 0000950170-25-110370
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-08-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025110370/0000950170-25-110370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025110370/itrm-20250820.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-110370
- JSON: https://secwatch.observer/filing/0000950170-25-110370.json
- Plain text: https://secwatch.observer/filing/0000950170-25-110370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.